title: What makes real world outcomes in soft tissue sarcomas? A mono-institutional trabectedin experience.
abstract: BACKGROUND
  Trabectedin proved its efficacy in relapsed advanced soft tissue sarcomas (STS) in 3 multicenter phase II studies with selected patients. The aim of the present study is to investigate trabectedin efficacy and tolerance in a cohort of "real-life" unselected patients with sarcoma.
  
  
  METHODS
  A single-center analysis was carried out on all consecutive patients with histologically proven unresectable advanced or metastatic STS, who received at least one cycle of trabectedin. Data on efficacy and tolerance were retrospectively reported.
  
  
  RESULTS
  From 2004 to 2014, data of 59 patients were reviewed. Median age was 62 years (from 23 to 87). A total of 317 cycles of trabectedin were administered. Twenty-five patients (42%) suffered grade 3-4 hematological toxicity, mainly with neutropenia (22 patients, 37%). Disease control rate was 24%, mainly with stable disease, and 45 patients (76%) experienced disease progression. Median overall survival was 6.6 months (95%CI [4.9-12.6]).
  
  
  CONCLUSIONS
  Trabectedin might be an option for patients without any other validated alternative, but phase III study evaluating trabectedin+best supportive care (BSC) versus BSC is necessary.
authors.affiliation: Institut de cancérologie Lucien-Neuwirth, département d'oncologie médicale, 42270 Saint-Priest-en-Jarez, France.
authors.forename: Guillaume
authors.initials: G
authors.lastname: Moriceau
authors.affiliation: Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 42270 Saint-Priest-en-Jarez, France.
authors.forename: Alexis
authors.initials: A
authors.lastname: Vallard
authors.affiliation: Institut de cancérologie Lucien-Neuwirth, département d'oncologie médicale, 42270 Saint-Priest-en-Jarez, France.
authors.forename: Benoîte
authors.initials: B
authors.lastname: Méry
authors.affiliation: Institut de cancérologie Lucien-Neuwirth, département d'oncologie médicale, 42270 Saint-Priest-en-Jarez, France.
authors.forename: Romain
authors.initials: R
authors.lastname: Rivoirard
authors.affiliation: Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 42270 Saint-Priest-en-Jarez, France.
authors.forename: Julien
authors.initials: J
authors.lastname: Langrand-Escure
authors.affiliation: Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 42270 Saint-Priest-en-Jarez, France.
authors.forename: Sophie
authors.initials: S
authors.lastname: Espenel
authors.affiliation: Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 42270 Saint-Priest-en-Jarez, France.
authors.forename: Majed
authors.initials: M
authors.lastname: Ben Mrad
authors.affiliation: Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 42270 Saint-Priest-en-Jarez, France.
authors.forename: Guoping
authors.initials: G
authors.lastname: Wang
authors.affiliation: Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 42270 Saint-Priest-en-Jarez, France.
authors.forename: Peng
authors.initials: P
authors.lastname: Diao
authors.affiliation: Institut de cancérologie Lucien-Neuwirth, département d'oncologie médicale, 42270 Saint-Priest-en-Jarez, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Fournel
authors.affiliation: Institut de cancérologie Lucien-Neuwirth, département d'oncologie médicale, 42270 Saint-Priest-en-Jarez, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Collard
authors.affiliation: Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 42270 Saint-Priest-en-Jarez, France. Electronic address: nicolas.magne@icloire.fr.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Magné
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004149:Dioxoles / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D012189:Retrospective Studies; D012509:Sarcoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D044005:Tetrahydroisoquinolines / Q000009:adverse effects / Q000627:therapeutic use*; D000077606:Trabectedin; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018906:Antineoplastic Agents, Alkylating; D004149:Dioxoles; D044005:Tetrahydroisoquinolines; D000077606:Trabectedin
keywords: Efficacité; Efficacy; Relapse; Récidive; Sarcome des tissus mous; Soft tissue sarcoma; Tolerance; Toxicité; Trabectedin; Trabectedine